Search Results

Hizentra will continue to be available in 5mL, 10mL and 20mL prefilled syringes as well as in 5mL, 10mL, 20mL, and 50mL vials.

https://newsroom.csl.com/2023-04-18-CSL-Behring-Receives-FDA-Approval-for-Hizentra-R-Immune-Globulin-Subcutaneous-Human-20-Liquid-50mL-Prefilled-Syringe

4,5

https://newsroom.csl.com/2020-11-05-CSL-Behring-Publishes-Design-for-First-Ever-Outcomes-Study-of-ApoA-I-to-Reduce-Risk-of-Cardiovascular-Events-in-Heart-Attack-Patients

If you have preexisting risk factors for liver cancer, regular liver health testing will continue for 5 years post-administration.

https://newsroom.csl.com/2023-12-11-CSL-Behrings-HEMGENIX-R-etranacogene-dezaparvovec-drlb-Demonstrates-at-Three-Years-Post-Treatment-Long-Term-Durability,-Safety-and-Greater-Bleed-Protection-Versus-Prophylactic-Treatment-in-People-Living-with-Hemophilia-B

5 - Speaker engagements Fees for services and con- - Advisory boards and other consulting engagements sultancy - Data analysis, medical writing and development of educational materials

https://www.csl.com/-/media/shared/documents/vifor-disclosures/methodological-notes/methodological-note-template-2024_final.pdf

The most commonly observed side effects associated with ANDEMBRY ® in the phase 3 clinical trial were injection site reactions (2/39, 5.1%) including redness, bruising and itchiness.

https://newsroom.csl.com/2025-02-26-Swissmedic-Approves-CSL-Behrings-ANDEMBRY-R-garadacimab-for-the-Prevention-of-Recurrent-Attacks-of-Hereditary-Angioedema-HAE

The most commonly observed side effects associated with ANDEMBRY ® in the phase 3 clinical trial were injection site reactions (2/39, 5.1%) including redness, bruising and itchiness.

https://newsroom.csl.com/2025-02-13-European-Commission-Approves-CSLs-ANDEMBRY-R-garadacimab-for-the-Prevention-of-Recurrent-Attacks-of-Hereditary-Angioedema-HAE

Limit the daily dose of simvastatin (20 mg) and rosuvastatin (5 mg).

https://newsroom.csl.com/2024-03-28-Vafseo-R-approved-by-the-U-S-FDA-for-the-treatment-of-anemia-due-to-chronic-kidney-disease-in-dialysis-dependent-adult-patients

Factor XIII deficiency affects the ability to stabilize blood clots. Learn more about Factor XIII deficiency, its symptoms and other informational resources.

https://www.csl.com/patients-public-health/rare-and-serious-diseases/hereditary-bleeding-disorders/factor-xiii-deficiency

Complete this form to apply for the award.

https://www.csl.com/research-and-development/awards-grants-and-initiatives/professor-heimburger-award/application

The mean monthly attack rate was 0.27 for patients treated with garadacimab versus 2.01 for those on placebo (N=25), with a median monthly attack rate of 0 for patients treated with garadacimab versus 1.35 for placebo, resulting in an attack rate reduction in means of 86.5% versus placebo and an attack rate reduction in medians of 100% versus placebo.

https://newsroom.csl.com/2023-03-01-The-Lancet-Publishes-Pivotal-Phase-3-Data-on-CSLs-First-in-Class-Garadacimab-for-HAE